New drug approved for refractory myeloma

On July 20, 2012, the FDA granted accelerated approval to Kyprolis (carfilzomib) for the treatment of patients with multiple myeloma who have received at least two prior therapies, including Velcade (bortezomib), Revlimid (lenalidomide) and thalidomide, and have demonstrated disease progression on or within 60 days of the completion of the last therapy.